<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416453</url>
  </required_header>
  <id_info>
    <org_study_id>CR107227</org_study_id>
    <secondary_id>VAC52150EBL2001</secondary_id>
    <secondary_id>2015-000596-27</secondary_id>
    <nct_id>NCT02416453</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults</brief_title>
  <official_title>A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of 3&#xD;
      vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as&#xD;
      2-dose heterologous regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, observer-blind, placebo-controlled, parallel-group, multicenter, Phase&#xD;
      2 study evaluating the safety, tolerability and immunogenicity of 2-dose heterologous&#xD;
      regimens using Ad26.ZEBOV and MVA-BN-Filo administered to healthy adults participants in&#xD;
      Europe. The study involves a screening period of up to 12 weeks, a vaccination period in&#xD;
      which participants will be vaccinated with Ad26.ZEBOV (dose 1) followed by vaccination with&#xD;
      MVA-BN-Filo (dose 2) 28, 56 or 84 days later, and a post-vaccination phase until 6 months&#xD;
      post dose 2 visit (Days 209, 237 or 265). After unblinding, only participants who received&#xD;
      Ad26.ZEBOV and/or MVA-BN-Filo will continue the study until the Day 365 visit (or until the&#xD;
      start of the roll-over study or for an additional 12 months [whichever comes first] for&#xD;
      participants in France who agree to continue the long-term follow-up after Day 365) to assess&#xD;
      long-term safety and immunogenicity. Participants will enroll into 3 cohorts: that is, Cohort&#xD;
      1 (Participants will receive Ad26.ZEBOV and MVA-BN-Filo in an open-label fashion), Cohort 2&#xD;
      (Participants will be randomized to receive the 2-dose heterologous vaccine regimen with&#xD;
      either Ad26.ZEBOV followed by MVA-BN-Filo, or placebo in a 14:1 ratio) and Cohort 3&#xD;
      (Participants will be randomized to receive the 2-dose heterologous vaccine regimen with&#xD;
      either Ad26.ZEBOV followed by MVA-BN-Filo, or placebo in a 10:3 ratio). In Cohorts 2 and 3,&#xD;
      core immunogenicity assessments (humoral and cellular assays) will be performed. In Cohort 2,&#xD;
      additional immunogenicity assessments will be done. In Cohort 1, plasma blast response&#xD;
      kinetics will be evaluated. Safety will be monitored during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2015</start_date>
  <completion_date type="Actual">January 19, 2018</completion_date>
  <primary_completion_date type="Actual">January 19, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events (Groups 1, 2 and 3)</measure>
    <time_frame>Up to 42-day post dose 2 visit (Day 1 to Day 127)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (Groups 1, 2 and 3)</measure>
    <time_frame>Up to Day 365</time_frame>
    <description>A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Immediate Reportable Events (Groups 1, 2 and 3)</measure>
    <time_frame>Up to Day 365</time_frame>
    <description>The following neuroinflammatory disorders were considered immediate reportable events and which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3)</measure>
    <time_frame>7 days post-dose 1 (Day 8)</time_frame>
    <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3)</measure>
    <time_frame>7 days post-dose 2 (Up to Day 92)</time_frame>
    <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3)</measure>
    <time_frame>7 days post-dose 1 (Day 8)</time_frame>
    <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3)</measure>
    <time_frame>7 days post-dose 2 (Up to Day 92)</time_frame>
    <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events (Group 4)</measure>
    <time_frame>Up to 28-day post dose 1 (Day 29)</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (Group 4)</measure>
    <time_frame>Up to Day 180</time_frame>
    <description>A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Immediate Reportable Events (Group 4)</measure>
    <time_frame>Up to Day 180</time_frame>
    <description>The following neuroinflammatory disorders were considered immediate reportable events which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Local Adverse Events (Group 4)</measure>
    <time_frame>7 days after each vaccination (Up to Day 8)</time_frame>
    <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Systemic Adverse Events (Group 4)</measure>
    <time_frame>7 days after each vaccination (Up to Day 8)</time_frame>
    <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Filovirus Animal Non-Clinical Group (FANG) Enzyme-linked Immunosorbent Assay (ELISA) (Groups 1, 2 and 3)</measure>
    <time_frame>At 21-days post dose 2 (Day 50 for Group 1; Day 78 for Group 2; and Day 106 for Group 3)</time_frame>
    <description>GMCs of antibodies binding to EBOV GP using FANG ELISA were reported and were measured in ELISA unit per milliliter (EU/mL). Serum samples were collected for analysis of binding antibodies against EBOV GP using FANG ELISA to determine humoral responses following vaccination. For ELISA binding antibody responses, values below the lower limit of quantification (LLOQ) (36.11 ELISA units/mL). The outcome measure was planned to be reported at 21-day post dose 2. Therefore, the results are reported for Group 1, 2 and 3 only.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">423</enrollment>
  <condition>Ebola Viral Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular (IM) injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 85.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-Filo</intervention_name>
    <description>One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit [Inf. U.] on Day 29, 57, or 85.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.ZEBOV</intervention_name>
    <description>One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be healthy in the Investigator's clinical judgment on the basis of medical&#xD;
             history, physical examination, electrocardiogram (ECG) and vital signs performed at&#xD;
             Screening&#xD;
&#xD;
          -  Must be healthy on the basis of clinical laboratory tests performed at Screening. If&#xD;
             the results of the laboratory screening tests are outside the normal reference ranges,&#xD;
             the participant may be included only if the Investigator judges the abnormalities or&#xD;
             deviations from normal to be not clinically significant or to be appropriate and&#xD;
             reasonable for the population under study&#xD;
&#xD;
          -  Before randomization, a woman must be either of childbearing potential and practicing&#xD;
             (or intending to practice) a highly effective method of birth control consistent with&#xD;
             local regulations regarding the use of birth control methods for participants&#xD;
             participating in clinical studies, beginning at least 28 days prior to vaccination OR&#xD;
             not of childbearing potential: postmenopausal (greater than [&gt;] 45 years of age with&#xD;
             amenorrhea for at least 2 years or lesser than or equal to [&lt;=] 45 years of age with&#xD;
             amenorrhea for at least 6 months, and a serum follicle stimulating hormone (FSH) level&#xD;
             &gt;40 international unit per milliliter [IU/L]); permanently sterilized (for example,&#xD;
             bilateral tubal occlusion [which includes tubal ligation procedures as consistent with&#xD;
             local regulations], hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or&#xD;
             otherwise be incapable of pregnancy&#xD;
&#xD;
          -  Woman of childbearing potential must have a negative serum (beta-human chorionic&#xD;
             gonadotropin [beta-hCG]) at Screening and a negative urine beta-hCG pregnancy test&#xD;
             immediately prior to each study vaccine administration&#xD;
&#xD;
          -  Man who is sexually active with a woman of childbearing potential and has not had a&#xD;
             vasectomy performed more than 1 year prior to screening must be willing to use condoms&#xD;
             for sexual intercourse beginning prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having received any candidate Ebola vaccine&#xD;
&#xD;
          -  Diagnosed with Ebola virus disease, or prior exposure to Ebola virus, including travel&#xD;
             to West Africa less than 1 month prior to screening. West Africa includes but is not&#xD;
             limited to the countries of Guinea, Liberia, Mali, and Sierra Leone&#xD;
&#xD;
          -  Having received any experimental candidate adenovirus serotype 26 (vector: Ad26) or&#xD;
             Modified Vaccinia Ankara (MVA-) based vaccine in the past&#xD;
&#xD;
          -  Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines&#xD;
             or vaccine products (including any of the constituents of the study vaccines including&#xD;
             known allergy to egg, egg products and aminoglycosides&#xD;
&#xD;
          -  Presence of acute illness or temperature greater than or equal to 38.0 C on Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inserm Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 10, 2015</study_first_submitted>
  <study_first_submitted_qc>April 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <results_first_submitted>January 15, 2021</results_first_submitted>
  <results_first_submitted_qc>January 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2021</results_first_posted>
  <disposition_first_submitted>January 17, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 17, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 22, 2019</disposition_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Ebola viruses</keyword>
  <keyword>Ebola Viral Disease (EVD)</keyword>
  <keyword>Filoviruses</keyword>
  <keyword>Monovalent vaccine</keyword>
  <keyword>Human adenovirus serotype 26 (Ad26) encoding the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)</keyword>
  <keyword>Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector (MVA-BN Filo)</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Inserm and University of Oxford</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02416453/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02416453/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 423 participants were randomized (408 participants in Groups 1 to 3 and 15 participants in Group 4). Among them, 421 participants received at least one dose of study vaccines. Two participants were randomized but not vaccinated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
          <description>Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5*10^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
        </group>
        <group group_id="P4">
          <title>Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 29.</description>
        </group>
        <group group_id="P5">
          <title>Group 1: Pooled Cohorts II and III: Placebo</title>
          <description>Participants received IM injection of placebo on Day 1 and Day 29.</description>
        </group>
        <group group_id="P6">
          <title>Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
        </group>
        <group group_id="P7">
          <title>Group 2: Pooled Cohorts II and III: Placebo</title>
          <description>Participants received IM injection of placebo on Day 1 and Day 57.</description>
        </group>
        <group group_id="P8">
          <title>Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
        </group>
        <group group_id="P9">
          <title>Group 3: Pooled Cohorts II and III: Placebo</title>
          <description>Participants received IM injection of placebo on Day 1 and Day 85.</description>
        </group>
        <group group_id="P10">
          <title>Group 4: Ad26.ZEBOV</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp on Day 1.</description>
        </group>
        <group group_id="P11">
          <title>Group 4: Placebo</title>
          <description>Participants received IM injection of placebo Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="112"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="114"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="106"/>
                <participants group_id="P9" count="18"/>
                <participants group_id="P10" count="13"/>
                <participants group_id="P11" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="97"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="98"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="94"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="13"/>
                <participants group_id="P11" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>PARTICIPANT UNABLE TO ATTEND ANY FURTHER</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>PARTICIPANT HAS MOVED TO SINGAPORE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
          <description>Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5*10^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
        </group>
        <group group_id="B4">
          <title>Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 29.</description>
        </group>
        <group group_id="B5">
          <title>Group 1: Pooled Cohorts II and III: Placebo</title>
          <description>Participants received IM injection of placebo on Day 1 and Day 29.</description>
        </group>
        <group group_id="B6">
          <title>Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
        </group>
        <group group_id="B7">
          <title>Group 2: Pooled Cohorts II and III: Placebo</title>
          <description>Participants received IM injection of placebo on Day 1 and Day 57.</description>
        </group>
        <group group_id="B8">
          <title>Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
        </group>
        <group group_id="B9">
          <title>Group 3: Pooled Cohorts II and III: Placebo</title>
          <description>Participants received IM injection of placebo on Day 1 and Day 85.</description>
        </group>
        <group group_id="B10">
          <title>Group 4: Ad26.ZEBOV</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp on Day 1.</description>
        </group>
        <group group_id="B11">
          <title>Group 4: Placebo</title>
          <description>Participants received IM injection of placebo Day 1.</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="112"/>
            <count group_id="B5" value="13"/>
            <count group_id="B6" value="114"/>
            <count group_id="B7" value="13"/>
            <count group_id="B8" value="106"/>
            <count group_id="B9" value="18"/>
            <count group_id="B10" value="13"/>
            <count group_id="B11" value="2"/>
            <count group_id="B12" value="421"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.2" spread="12.95"/>
                    <measurement group_id="B2" value="47.4" spread="16.53"/>
                    <measurement group_id="B3" value="38.7" spread="13.99"/>
                    <measurement group_id="B4" value="41" spread="15"/>
                    <measurement group_id="B5" value="39.1" spread="13.9"/>
                    <measurement group_id="B6" value="41" spread="14.02"/>
                    <measurement group_id="B7" value="38.2" spread="13.66"/>
                    <measurement group_id="B8" value="38.3" spread="14.34"/>
                    <measurement group_id="B9" value="41.1" spread="15.11"/>
                    <measurement group_id="B10" value="37.9" spread="11.37"/>
                    <measurement group_id="B11" value="47" spread="4.24"/>
                    <measurement group_id="B12" value="40" spread="14.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="62"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="53"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="217"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="53"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="10"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="97"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="102"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="89"/>
                    <measurement group_id="B9" value="16"/>
                    <measurement group_id="B10" value="10"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="365"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="55"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="50"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="13"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="59"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="56"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Unsolicited Adverse Events (Groups 1, 2 and 3)</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits.</description>
        <time_frame>Up to 42-day post dose 2 visit (Day 1 to Day 127)</time_frame>
        <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5*10^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O4">
            <title>Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Group 1: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O7">
            <title>Group 2: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 57.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Adverse Events (Groups 1, 2 and 3)</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits.</description>
          <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="106"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="52"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="46"/>
                    <measurement group_id="O9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events (Groups 1, 2 and 3)</title>
        <description>A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Up to Day 365</time_frame>
        <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5*10^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O4">
            <title>Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Group 1: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O7">
            <title>Group 2: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 57.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (Groups 1, 2 and 3)</title>
          <description>A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="106"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Immediate Reportable Events (Groups 1, 2 and 3)</title>
        <description>The following neuroinflammatory disorders were considered immediate reportable events and which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.</description>
        <time_frame>Up to Day 365</time_frame>
        <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5*10^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O4">
            <title>Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Group 1: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O7">
            <title>Group 2: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 57.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immediate Reportable Events (Groups 1, 2 and 3)</title>
          <description>The following neuroinflammatory disorders were considered immediate reportable events and which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.</description>
          <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="106"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3)</title>
        <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.</description>
        <time_frame>7 days post-dose 1 (Day 8)</time_frame>
        <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5*10^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O4">
            <title>Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Group 1: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O7">
            <title>Group 2: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 57.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3)</title>
          <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.</description>
          <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="106"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="65"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="78"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3)</title>
        <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.</description>
        <time_frame>7 days post-dose 2 (Up to Day 92)</time_frame>
        <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5*10^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O4">
            <title>Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Group 1: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O7">
            <title>Group 2: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 57.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3)</title>
          <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.</description>
          <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="91"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="83"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="62"/>
                <count group_id="O9" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="49"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="41"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3)</title>
        <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.</description>
        <time_frame>7 days post-dose 1 (Day 8)</time_frame>
        <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5*10^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O4">
            <title>Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Group 1: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O7">
            <title>Group 2: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 57.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3)</title>
          <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.</description>
          <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="114"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="106"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="84"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="82"/>
                    <measurement group_id="O9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3)</title>
        <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.</description>
        <time_frame>7 days post-dose 2 (Up to Day 92)</time_frame>
        <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5*10^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O4">
            <title>Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Group 1: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O7">
            <title>Group 2: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 57.</description>
          </group>
          <group group_id="O8">
            <title>Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O9">
            <title>Group 3: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3)</title>
          <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.</description>
          <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="91"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="83"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="62"/>
                <count group_id="O9" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="38"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unsolicited Adverse Events (Group 4)</title>
        <description>An AE is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits.</description>
        <time_frame>Up to 28-day post dose 1 (Day 29)</time_frame>
        <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 4: Ad26.ZEBOV</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 4: Placebo</title>
            <description>Participants received IM injection of placebo Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Adverse Events (Group 4)</title>
          <description>An AE is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected manner at study visits.</description>
          <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (Group 4)</title>
        <description>A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Up to Day 180</time_frame>
        <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 4: Ad26.ZEBOV</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 4: Placebo</title>
            <description>Participants received IM injection of placebo Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (Group 4)</title>
          <description>A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Immediate Reportable Events (Group 4)</title>
        <description>The following neuroinflammatory disorders were considered immediate reportable events which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.</description>
        <time_frame>Up to Day 180</time_frame>
        <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 4: Ad26.ZEBOV</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 4: Placebo</title>
            <description>Participants received IM injection of placebo Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immediate Reportable Events (Group 4)</title>
          <description>The following neuroinflammatory disorders were considered immediate reportable events which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.</description>
          <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Local Adverse Events (Group 4)</title>
        <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.</description>
        <time_frame>7 days after each vaccination (Up to Day 8)</time_frame>
        <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 4: Ad26.ZEBOV</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 4: Placebo</title>
            <description>Participants received IM injection of placebo Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local Adverse Events (Group 4)</title>
          <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.</description>
          <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Systemic Adverse Events (Group 4)</title>
        <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.</description>
        <time_frame>7 days after each vaccination (Up to Day 8)</time_frame>
        <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 4: Ad26.ZEBOV</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Group 4: Placebo</title>
            <description>Participants received IM injection of placebo Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Systemic Adverse Events (Group 4)</title>
          <description>An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.</description>
          <population>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Filovirus Animal Non-Clinical Group (FANG) Enzyme-linked Immunosorbent Assay (ELISA) (Groups 1, 2 and 3)</title>
        <description>GMCs of antibodies binding to EBOV GP using FANG ELISA were reported and were measured in ELISA unit per milliliter (EU/mL). Serum samples were collected for analysis of binding antibodies against EBOV GP using FANG ELISA to determine humoral responses following vaccination. For ELISA binding antibody responses, values below the lower limit of quantification (LLOQ) (36.11 ELISA units/mL). The outcome measure was planned to be reported at 21-day post dose 2. Therefore, the results are reported for Group 1, 2 and 3 only.</description>
        <time_frame>At 21-days post dose 2 (Day 50 for Group 1; Day 78 for Group 2; and Day 106 for Group 3)</time_frame>
        <population>The per protocol analysis set included all randomized and vaccinated participants, who received both the prime and boost vaccinations (administered within the protocol-defined window), have at least 1 post-vaccination (that is, after the date of vaccination) evaluable immunogenicity sample, and have no major protocol violations influencing the immune response. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 57.</description>
          </group>
          <group group_id="O5">
            <title>Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)</title>
            <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
          </group>
          <group group_id="O6">
            <title>Group 3: Pooled Cohorts II and III: Placebo</title>
            <description>Participants received IM injection of placebo on Day 1 and Day 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Filovirus Animal Non-Clinical Group (FANG) Enzyme-linked Immunosorbent Assay (ELISA) (Groups 1, 2 and 3)</title>
          <description>GMCs of antibodies binding to EBOV GP using FANG ELISA were reported and were measured in ELISA unit per milliliter (EU/mL). Serum samples were collected for analysis of binding antibodies against EBOV GP using FANG ELISA to determine humoral responses following vaccination. For ELISA binding antibody responses, values below the lower limit of quantification (LLOQ) (36.11 ELISA units/mL). The outcome measure was planned to be reported at 21-day post dose 2. Therefore, the results are reported for Group 1, 2 and 3 only.</description>
          <population>The per protocol analysis set included all randomized and vaccinated participants, who received both the prime and boost vaccinations (administered within the protocol-defined window), have at least 1 post-vaccination (that is, after the date of vaccination) evaluable immunogenicity sample, and have no major protocol violations influencing the immune response. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4627" lower_limit="3649" upper_limit="5867"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="55">Here, 'NA' signifies that Geometric mean and lower limit of 95% CI were not calculated because post dose values were less than LLOQ (36.11 ELISA units/mL).</measurement>
                    <measurement group_id="O3" value="10131" lower_limit="8554" upper_limit="11999"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Here, 'NA' signifies that Geometric mean and CI were not calculated because post dose values were less than LLOQ (36.11 ELISA units/mL).</measurement>
                    <measurement group_id="O5" value="11312" lower_limit="9072" upper_limit="14106"/>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Here, 'NA' signifies that Geometric mean and CI were not calculated because post dose values were less than LLOQ (36.11 ELISA units/mL).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 365</time_frame>
      <desc>Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo), regardless of the occurrence of protocol deviations.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
          <description>Participants received intramuscular (IM) injection of Ad26.ZEBOV at 5*10^10 viral particles (vp) as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 infectious units (Inf.U) (nominal titer) as dose 2 on Day 29.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
        </group>
        <group group_id="E4">
          <title>Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 29.</description>
        </group>
        <group group_id="E5">
          <title>Group 1: Pooled Cohorts II and III: Placebo</title>
          <description>Participants received IM injection of placebo on Day 1 and Day 29.</description>
        </group>
        <group group_id="E6">
          <title>Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 57.</description>
        </group>
        <group group_id="E7">
          <title>Group 2: Pooled Cohorts II and III: Placebo</title>
          <description>Participants received IM injection of placebo on Day 1 and Day 57.</description>
        </group>
        <group group_id="E8">
          <title>Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp as dose 1 on Day 1 followed by IM injection of MVA-BN-filo at 1*10^8 Inf.U (nominal titer) as dose 2 on Day 85.</description>
        </group>
        <group group_id="E9">
          <title>Group 3: Pooled Cohorts II and III: Placebo</title>
          <description>Participants received IM injection of placebo on Day 1 and Day 85.</description>
        </group>
        <group group_id="E10">
          <title>Group 4: Ad26.ZEBOV</title>
          <description>Participants received IM injection of Ad26.ZEBOV at 5*10^10 vp on Day 1.</description>
        </group>
        <group group_id="E11">
          <title>Group 4: Placebo</title>
          <description>Participants received IM injection of placebo Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Human papilloma virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Osteosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Miller Fisher syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Small fibre neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="26" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dental discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Leader</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <phone>844-434-4210</phone>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

